GlassScriptPhysician profile
Lacy Burns
NPI 1285263970
$7,964.49
in general payments reported to CMS, 2019-2025
36 companies · $2,145 in 2025
The $2,145 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $76.95 · 2022: $1,338 · 2023: $2,029 · 2024: $2,376 · 2025: $2,145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,550.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,549.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,523.75 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,164.96 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $848.71 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $653.28 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $607.45 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Otsuka America Pharmaceutical, INC. | $273.31 | 2022-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $261.36 | 2023-2025 | Caplyta |
| Amgen INC. | $248.77 | 2022-2024 | Otezla, Repatha |
| Mylan Specialty L.P. | $236.54 | 2022-2023 | Yupelri |
| Axsome Therapeutics, INC. | $230.51 | 2023-2025 | Auvelity, Symbravo |
| Inspire Medical Systems, INC. | $179.64 | 2024 | Inspire |
| Bayer Healthcare Pharmaceuticals INC. | $178.96 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.88 | 2023-2025 | Jardiance, Synjardy |
| Idorsia Pharmaceuticals US INC | $155.38 | 2022-2024 | Quviviq |
| Aimmune Therapeutics, INC. | $154.28 | 2024-2025 | Zenpep |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $133.28 | 2023-2025 | |
| Astellas Pharma US INC | $91.74 | 2023-2025 | Veozah, Myrbetriq |
| Corcept Therapeutics | $90.27 | 2024-2025 | Korlym |
| Dexcom, INC. | $90.18 | 2024-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Merck Sharp & Dohme LLC | $69.75 | 2022-2023 | Verquvo, Belsomra, Steglatro |
| Exact Sciences Corporation | $67.91 | 2023-2025 | Cologuard Collection Kit |
| Philips North America LLC | $58.07 | 2022-2024 | (Ck7) Extended Holter |
| Scpharmaceuticals INC. | $53.30 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.72 | 2024-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $50.90 | 2022-2024 | Xarelto, Spravato |
| Lundbeck LLC | $47.22 | 2025 | Vyepti |
| Shield Therapeutics INC | $45.36 | 2023-2024 | Accrufer |
| Sanofi-Aventis U.S. LLC | $41.77 | 2022-2023 | |
| Vanda Pharmaceuticals INC. | $39.21 | 2025 | Fanapt |
| Almatica Pharma LLC | $36.19 | 2023-2024 | Loreev Xr, Gralise |
| Phathom Pharmaceuticals, INC. | $29.87 | 2025 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $21.20 | 2022 | |
| Eisai INC. | $21.17 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.99 | 2024 | Trintellix |
| Nestle Healthcare Nutrition INC. | $16.00 | 2023 | |
| Currax Pharmaceuticals LLC | $15.61 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lacy Burns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.